Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2020 16:15 ET | Source: ARCA biopharma, Inc.

Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update

AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...
May 06, 2020 16:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update

U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
April 23, 2019 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

WESTMINSTER, Colo., April 23, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 27, 2019 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 20, 2019 07:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...

keyboard_arrow_left Previous Page